Astrid E. Cardona

Dr. Astrid E. Cardona

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2006 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
ACAstrid E. Cardona
Astrid E. Cardona
EPErik P Pioro
Erik P Pioro
MSMargaret E Sasse
Margaret E Sasse
VKVolodymyr Kostenko
Volodymyr Kostenko
SCSandra M Cardona
Sandra M Cardona
RRRichard M Ransohoff
Richard M Ransohoff

10 November 2010 in Nature
Verified
Journal Article
Closed access
RRRichard M. Ransohoff
Richard M. Ransohoff
ACAstrid E. Cardona
Astrid E. Cardona

27 October 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NSNoah Saederup
Noah Saederup
ACAstrid E. Cardona
Astrid E. Cardona
KCKelsey Croft
Kelsey Croft
MMMakiko Mizutani
Makiko Mizutani
ACAnne C. Cotleur
Anne C. Cotleur
ICIsrael F. Charo
Israel F. Charo
Monocyte subpopulations distinguished by differential expression of chemokine receptors CCR2 and CX3CR1 are difficult to track in vivo, partly due to lack of CCR2 reagents. We created CCR2-red fluorescent protein (RFP) knock-in mice and crossed them with CX3CR1-GFP mice to investigate monocyte subset trafficking. In mice with experimental autoimmune encephalomyelitis, CCR2 was critical for efficient intrathecal accumulation and localization of Ly6Chi/CCR2hi monocytes. Surprisingly, neutrophils, not Ly6Clo monocytes, largely replaced Ly6Chi cells in the central nervous system of these mice. CCR2-RFP expression allowed the first unequivocal distinction between infiltrating monocytes/macrophages from resident microglia. These results refine the concept of monocyte subsets, provide mechanistic insight about monocyte entry into the central nervous system, and present a novel model for imaging and quantifying inflammatory myeloid populations.

1 October 2010 in Neuron
Verified
Journal Article
Closed access
KBKiran Bhaskar
Kiran Bhaskar
MKMegan Konerth
Megan Konerth
OKOlga N. Kokiko-Cochran
Olga N. Kokiko-Cochran
ACAstrid E. Cardona
Astrid E. Cardona
RRRichard M. Ransohoff
Richard M. Ransohoff
BLBruce T. Lamb
Bruce T. Lamb

30 March 2015 in Brain
Verified
Journal Article
Open access
PDF file
NMNicole Maphis
Nicole Maphis
GXGuixiang Xu
Guixiang Xu
OKOlga N. Kokiko-Cochran
Olga N. Kokiko-Cochran
SJShanya Jiang
Shanya Jiang
ACAstrid E. Cardona
Astrid E. Cardona
KBKiran Bhaskar
Kiran Bhaskar
Pathological aggregation of tau is a hallmark of Alzheimer’s disease and related tauopathies. We have previously shown that the deficiency of the microglial fractalkine receptor (CX3CR1) led to the acceleration of tau pathology and memory impairment in an hTau mouse model of tauopathy. Here, we show that microglia drive tau pathology in a cell-autonomous manner. First, tau hyperphosphorylation and aggregation occur as early as 2 months of age in hTauCx3cr1−/− mice. Second, CD45+ microglial activation correlates with the spatial memory deficit and spread of tau pathology in the anatomically connected regions of the hippocampus. Third, adoptive transfer of purified microglia derived from hTauCx3cr1−/− mice induces tau hyperphosphorylation within the brains of non-transgenic recipient mice. Finally, inclusion of interleukin 1 receptor antagonist (Kineret®) in the adoptive transfer inoculum significantly reduces microglia-induced tau pathology. Together, our results suggest that reactive microglia are sufficient to drive tau pathology and correlate with the spread of pathological tau in the brain.

1 November 2010 in The American Journal of Pathology
Verified
Journal Article
Closed access
SLSungho Lee
Sungho Lee
NVNicholas H. Varvel
Nicholas H. Varvel
MKMegan E. Konerth
Megan E. Konerth
GXGuixiang Xu
Guixiang Xu
ACAstrid E. Cardona
Astrid E. Cardona
BLBruce T. Lamb
Bruce T. Lamb